Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arecor Therapeutics's enterprise value is €19.86 Mil.
Arecor Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.32 Mil. Therefore, Arecor Therapeutics's EV-to-EBITDA for today is 15.10.
The historical rank and industry rank for Arecor Therapeutics's EV-to-EBITDA or its related term are showing as below:
STU:6UI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.37 Med: -4.52 Max: 22.86
Current: 13.97
During the past 9 years, the highest EV-to-EBITDA of Arecor Therapeutics was 22.86. The lowest was -35.37. And the median was -4.52.
STU:6UI's EV-to-EBITDA is ranked worse than 54.99% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs STU:6UI: 13.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arecor Therapeutics's PE Ratio (TTM) for today is calculated as:
Arecor Therapeutics's share price for today is €0.685.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Arecor Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6UI vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Arecor Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's EV-to-EBITDA falls into.
Arecor Therapeutics's current Enterprise Value is €19.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (STU:6UI) has a EV-to-EBITDA of 15.10 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arecor Therapeutics. According to the industry distribution chart, Arecor Therapeutics ranks #226 out of 411 companies in the Biotechnology industry, placing it in the top 55%.
Is Arecor Therapeutics' EV-to-EBITDA too high?
Arecor Therapeutics' current EV-to-EBITDA is 15.10. The Biotechnology industry median EV-to-EBITDA is 12.05. Arecor Therapeutics' value of 15.10 is 25.3% above this industry median. Based on the distribution chart, Arecor Therapeutics ranks #226 out of 411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #226 out of 411 companies for EV-to-EBITDA. This places Arecor Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. Arecor Therapeutics' value of 15.10 is 25.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arecor Therapeutics's current EV-to-EBITDA of 15.10 is 25.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arecor Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current EV-to-EBITDA is 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current EV-to-EBITDA of 15.10. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current EV-to-EBITDA is 15.10 and 25.3% above the Biotechnology industry median of 12.05. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current EV-to-EBITDA is 15.10 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
EV-to-EBITDA: 15.10
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
Industry Position: 25.3% above the Biotechnology median (#226 of 411)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for STU:6UI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
